Company intelligence / Profile preview

Fanavaran Rojan Mohaghegh Daru

Tehran, Iran

Ownership: Private
Development stage: Other

Overview

Fanavaran Rojan Mohaghegh Daru manufactures and supplies the combination antiviral Sovodak (sofosbuvir/daclatasvir), which has reached randomized clinical trials and appears widely used in the treatment of hepatitis C and evaluated for COVID-19. Clinical studies have shown Sovodak to be safe, with some COVID-19 trials indicating signals of improved outcomes but at least one large Phase III trial did not show statistically significant differences on hospital discharge or mortality compared to placebo.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Rojianz

Unknown

Beyond the preview

Go deeper on Fanavaran Rojan Mohaghegh Daru.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fanavaran Rojan Mohaghegh Daru.

Explore the full profile